US6569679B1
(en)
*
|
1988-03-21 |
2003-05-27 |
Chiron Corporation |
Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene
|
US5997859A
(en)
*
|
1988-03-21 |
1999-12-07 |
Chiron Corporation |
Method for treating a metastatic carcinoma using a conditionally lethal gene
|
US6605712B1
(en)
*
|
1990-12-20 |
2003-08-12 |
Arch Development Corporation |
Gene transcription and ionizing radiation: methods and compositions
|
US5631236A
(en)
|
1993-08-26 |
1997-05-20 |
Baylor College Of Medicine |
Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
|
FR2712602B1
(fr)
*
|
1993-11-18 |
1996-02-09 |
Centre Nat Rech Scient |
Virus recombinants, préparation et utilisation en thérapie génique.
|
WO1995014091A2
(en)
*
|
1993-11-18 |
1995-05-26 |
Chiron Viagene, Inc. |
Compositions and methods for utilizing conditionally lethal genes
|
US5670347A
(en)
|
1994-05-11 |
1997-09-23 |
Amba Biosciences Llc |
Peptide-mediated gene transfer
|
CA2156132A1
(en)
|
1994-08-16 |
1996-02-17 |
Abraham Bout |
Recombinant vectors derived from adenovirus for use in gene therapy
|
US5688773A
(en)
*
|
1994-08-17 |
1997-11-18 |
The General Hospital Corporation |
Method of selectively destroying neoplastic cells
|
US5998205A
(en)
*
|
1994-11-28 |
1999-12-07 |
Genetic Therapy, Inc. |
Vectors for tissue-specific replication
|
US6638762B1
(en)
*
|
1994-11-28 |
2003-10-28 |
Genetic Therapy, Inc. |
Tissue-vectors specific replication and gene expression
|
AU5300396A
(en)
*
|
1995-03-01 |
1996-09-18 |
Human Gene Therapy Research Institute |
Radiation enhanced gene therapy for treatment of tumors
|
US6974571B2
(en)
|
1995-03-28 |
2005-12-13 |
Thomas Jefferson University |
Isolated stromal cells and methods of using the same
|
ES2266715T3
(es)
*
|
1995-03-28 |
2007-03-01 |
Thomas Jefferson University |
Implantes que comprenden celulas estromales aisladas inmunologicamente y su utilizacion.
|
AU5738996A
(en)
*
|
1995-05-11 |
1996-11-29 |
Genetic Therapy, Inc. |
Gene therapy through transduction of oral epithelial cells
|
US6190657B1
(en)
|
1995-06-07 |
2001-02-20 |
Yale University |
Vectors for the diagnosis and treatment of solid tumors including melanoma
|
US20020068049A1
(en)
*
|
1998-09-10 |
2002-06-06 |
Henderson Daniel R. |
Tissue specific adenoviral vectors
|
US5789244A
(en)
*
|
1996-01-08 |
1998-08-04 |
Canji, Inc. |
Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
|
US6392069B2
(en)
|
1996-01-08 |
2002-05-21 |
Canji, Inc. |
Compositions for enhancing delivery of nucleic acids to cells
|
US20040014709A1
(en)
*
|
1996-01-08 |
2004-01-22 |
Canji, Inc. |
Methods and compositions for interferon therapy
|
US7002027B1
(en)
|
1996-01-08 |
2006-02-21 |
Canji, Inc. |
Compositions and methods for therapeutic use
|
US5998384A
(en)
*
|
1996-01-26 |
1999-12-07 |
Hisamitsu Pharmaceutical Co., Inc. |
Endoscopic administration of an HSV-tk gene to treat digestive organ cancer
|
DE19605279A1
(de)
*
|
1996-02-13 |
1997-08-14 |
Hoechst Ag |
Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
|
US5948681A
(en)
*
|
1996-08-14 |
1999-09-07 |
Children's Hospital Of Philadelphia |
Non-viral vehicles for use in gene transfer
|
US6610839B1
(en)
*
|
1997-08-14 |
2003-08-26 |
Geron Corporation |
Promoter for telomerase reverse transcriptase
|
US6777203B1
(en)
|
1997-11-19 |
2004-08-17 |
Geron Corporation |
Telomerase promoter driving expression of therapeutic gene sequences
|
AU4908197A
(en)
*
|
1996-10-18 |
1998-05-15 |
Valentis, Inc. |
Gene expression and delivery systems and uses
|
WO1998017801A1
(en)
*
|
1996-10-18 |
1998-04-30 |
Canji, Inc. |
METHODS AND COMPOSITIONS FOR DELIVERY AND EXPRESSION OF INTERFERON-α NUCLEIC ACIDS
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
US5772993A
(en)
*
|
1997-01-21 |
1998-06-30 |
The University Of Virginia Patent Foundation |
Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
|
PT973550E
(pt)
|
1997-04-11 |
2003-01-31 |
Searle & Co |
Anticorpos antagonistas anti-integrina avb3
|
WO1998046265A1
(en)
|
1997-04-11 |
1998-10-22 |
G.D. Searle & Co. |
Methods for using antagonistic anti-avb3 integrin antibodies
|
US6096718A
(en)
*
|
1997-06-05 |
2000-08-01 |
Gene Targeting Corp. |
Tissue specific adenovirus vectors for breast cancer treatment
|
US6207648B1
(en)
|
1997-07-24 |
2001-03-27 |
Trustees Of Boston University |
Methods of using cytochrome P450 reductase for the enhancement of P450-based anti-cancer gene therapy
|
US6696423B1
(en)
|
1997-08-29 |
2004-02-24 |
Biogen, Inc. |
Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
|
US6080849A
(en)
|
1997-09-10 |
2000-06-27 |
Vion Pharmaceuticals, Inc. |
Genetically modified tumor-targeted bacteria with reduced virulence
|
US7378244B2
(en)
*
|
1997-10-01 |
2008-05-27 |
Geron Corporation |
Telomerase promoters sequences for screening telomerase modulators
|
US6087164A
(en)
|
1997-10-03 |
2000-07-11 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Methods and compositions for inducing tumor-specific cytotoxicity
|
US7041654B2
(en)
|
1997-10-03 |
2006-05-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Methods and compositions for inducing tumor-specific cytotoxicity
|
WO1999019485A1
(en)
|
1997-10-16 |
1999-04-22 |
Children's Medical Center Corporation |
THYMOSIN β15 PROMOTER AND USE THEREOF
|
CA2308606A1
(en)
|
1997-11-06 |
1999-05-20 |
Chiron S.P.A. |
Neisserial antigens
|
DE69941567D1
(de)
|
1998-01-14 |
2009-12-03 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
CA2319468A1
(en)
*
|
1998-02-03 |
1999-08-12 |
Inex Pharmaceuticals Corporation |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
ATE344322T1
(de)
|
1998-02-13 |
2006-11-15 |
Koester Hubert |
Verwendung von ribozymen zur bestimmung der funktion von genen
|
FR2777570A1
(fr)
*
|
1998-04-17 |
1999-10-22 |
Transgene Sa |
Mutant ayant une activite phosphoribosyl transferase
|
CN101293920B
(zh)
|
1998-05-01 |
2012-07-18 |
诺华疫苗和诊断公司 |
脑膜炎奈瑟球菌抗原和组合物
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US20030017138A1
(en)
*
|
1998-07-08 |
2003-01-23 |
Menzo Havenga |
Chimeric adenoviruses
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
US6552005B1
(en)
*
|
1998-09-29 |
2003-04-22 |
Uab Research Foundation |
Molecular chemotherapy enhancement of radiotherapy
|
GB9824437D0
(en)
*
|
1998-11-06 |
1999-01-06 |
Ylo Herttuala Seppo |
Gene therapy
|
US6929946B1
(en)
*
|
1998-11-20 |
2005-08-16 |
Crucell Holland B.V. |
Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
|
US6573090B1
(en)
|
1998-12-09 |
2003-06-03 |
The General Hospital Corporation |
Enhanced packaging of herpes virus amplicons and generation of recombinant virus vectors
|
US6869936B1
(en)
|
1999-03-04 |
2005-03-22 |
Crucell Holland B.V. |
Means and methods for fibroblast-like or macrophage-like cell transduction
|
WO2000058479A1
(en)
|
1999-03-26 |
2000-10-05 |
Amgen Inc. |
Beta secretase genes and polypeptides
|
US6677155B1
(en)
|
1999-04-22 |
2004-01-13 |
The General Hospital Corporation |
Triple hybrid amplicon vector systems to generate retroviral packaging lines
|
NZ530640A
(en)
|
1999-04-30 |
2006-06-30 |
Chiron S |
Conserved neisserial antigens
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
EP1185627A2
(de)
*
|
1999-06-01 |
2002-03-13 |
Cornell Research Foundation, Inc. |
Aktivierung von dendritischen zellen zur verstärkung der immunität
|
WO2000072686A1
(en)
*
|
1999-06-02 |
2000-12-07 |
Cell Genesys, Inc. |
Regulation of systemic immune responses utilizing cytokines and antigens
|
US6673602B1
(en)
|
1999-06-11 |
2004-01-06 |
The General Hospital Corporation |
Herpes simplex virus amplicon vector targeting system and method of using same
|
US7589069B1
(en)
*
|
1999-07-12 |
2009-09-15 |
Saint Louis University |
Replication-competent anti-cancer vectors
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
WO2001005229A1
(en)
|
1999-07-15 |
2001-01-25 |
The General Hospital Corporation |
Non-defective epstein-barr viral vector
|
US6770632B1
(en)
|
1999-07-16 |
2004-08-03 |
The General Hospital Corporation |
Folypolyglutamyl synthetase gene transfer to enhance antifolate
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US6900043B1
(en)
*
|
1999-09-21 |
2005-05-31 |
Amgen Inc. |
Phosphatases which activate map kinase pathways
|
CA2386806A1
(en)
*
|
1999-10-04 |
2001-04-12 |
Vion Pharmaceuticals, Inc. |
Non-invasive tumor imaging by tumor-targeted bacteria
|
US6962696B1
(en)
|
1999-10-04 |
2005-11-08 |
Vion Pharmaceuticals Inc. |
Compositions and methods for tumor-targeted delivery of effector molecules
|
GB9924981D0
(en)
*
|
1999-10-21 |
1999-12-22 |
Univ Manchester |
Gene therapy
|
US6716824B1
(en)
*
|
1999-10-22 |
2004-04-06 |
F. Charles Brunicardi |
Treatment of pancreatic adenocarcinoma by cytotoxic gene therapy
|
AU784203B2
(en)
|
1999-10-29 |
2006-02-23 |
Glaxosmithkline Biologicals S.A. |
Neisserial antigenic peptides
|
RU2279889C2
(ru)
|
2000-01-17 |
2006-07-20 |
Чирон С.Р.Л. |
ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
|
US20050239061A1
(en)
*
|
2000-03-01 |
2005-10-27 |
Marshall William S |
Identification and use of effectors and allosteric molecules for the alteration of gene expression
|
JP2003525911A
(ja)
*
|
2000-03-08 |
2003-09-02 |
ニューロサーチ、アクティーゼルスカブ |
プロドラッグに対する内皮細胞の感受性を高める方法
|
US6897020B2
(en)
|
2000-03-20 |
2005-05-24 |
Newlink Genetics Inc. |
Methods and compositions for elucidating relative protein expression levels in cells
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
GB0008966D0
(en)
*
|
2000-04-13 |
2000-05-31 |
Imp College Innovations Ltd |
Vectors for gene therapy
|
US6331528B1
(en)
*
|
2000-04-25 |
2001-12-18 |
Ajinomoto Co., Inc. |
Method for treatment in gene therapy and use of guanine derivative therefor
|
PT2077279E
(pt)
|
2000-06-28 |
2012-09-14 |
Amgen Inc |
Moléculas do receptor de linfopoietina estromal tímica e suas utilizações
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
AU2003222427B8
(en)
|
2000-11-17 |
2010-04-29 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same
|
US8071740B2
(en)
|
2000-11-17 |
2011-12-06 |
Vascular Biogenics Ltd. |
Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
|
WO2002042468A2
(en)
|
2000-11-27 |
2002-05-30 |
Geron Corporation |
Glycosyltransferase vectors for treating cancer
|
US6576464B2
(en)
|
2000-11-27 |
2003-06-10 |
Geron Corporation |
Methods for providing differentiated stem cells
|
US6921665B2
(en)
*
|
2000-11-27 |
2005-07-26 |
Roslin Institute (Edinburgh) |
Selective antibody targeting of undifferentiated stem cells
|
US20020107219A1
(en)
*
|
2000-12-05 |
2002-08-08 |
Curiel David T. |
Adenoviral vector containing cyclooxygenase-2 promoter and uses thereof
|
US6794376B2
(en)
*
|
2000-12-06 |
2004-09-21 |
William Beaumont Hospital |
Methods and compositions for enhancing diffusion of therapeutic agents through tissue
|
WO2002053576A1
(en)
*
|
2001-01-05 |
2002-07-11 |
The General Hospital Corporation |
Viral delivery system for infectious transfer of large genomic dna inserts
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
CA2440890C
(en)
*
|
2001-03-27 |
2011-07-19 |
New York University |
Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
|
WO2002080849A2
(en)
*
|
2001-04-06 |
2002-10-17 |
University Of Chicago |
Chemotherapeutic induction of egr-1 promoter activity
|
US20040242523A1
(en)
*
|
2003-03-06 |
2004-12-02 |
Ana-Farber Cancer Institue And The Univiersity Of Chicago |
Chemo-inducible cancer gene therapy
|
US8034791B2
(en)
|
2001-04-06 |
2011-10-11 |
The University Of Chicago |
Activation of Egr-1 promoter by DNA damaging chemotherapeutics
|
US8058248B2
(en)
*
|
2001-04-26 |
2011-11-15 |
The United States Of America As Represented By The Secretary Of Agriculture |
Foot and mouth disease virus vaccine comprising interferons
|
US20030003074A1
(en)
*
|
2001-06-14 |
2003-01-02 |
Macromed, Inc. |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
US20060159657A1
(en)
*
|
2001-06-14 |
2006-07-20 |
Macromed, Incorporated |
Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
|
AU2002322493A1
(en)
*
|
2001-07-10 |
2003-01-29 |
Ams Research Corporation |
Surgical kit for treating prostate tissue
|
CA2452517A1
(en)
*
|
2001-07-11 |
2003-01-23 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
US20140088177A1
(en)
*
|
2001-07-11 |
2014-03-27 |
University Of Miami |
Recombinant vsv for the treatment of tumor cells
|
AU2008201293B2
(en)
*
|
2001-07-11 |
2011-08-18 |
University Of Miami |
Recombinant VSV for the treatment of tumor cells
|
US20030032597A1
(en)
*
|
2001-07-31 |
2003-02-13 |
Sebestyen Magdolna G. |
Targeting nucleic acids to a cellular nucleus
|
US7232672B2
(en)
*
|
2001-08-03 |
2007-06-19 |
Diversa Corporation |
P450 enzymes, nucleic acids encoding them and methods of making and using them
|
WO2003014140A1
(en)
*
|
2001-08-09 |
2003-02-20 |
Board Of Trustees Of The University Of Arkansas |
Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
|
KR100491299B1
(ko)
|
2001-09-29 |
2005-05-24 |
학교법인연세대학교 |
개선된 질환 치료 효과를 갖는 재조합 아데노바이러스 및그를 포함하는 약제학적 조성물
|
US20040086485A1
(en)
*
|
2001-10-04 |
2004-05-06 |
Aguilar-Cordova Carlos Estuardo |
Chemeric viral vectors for gene therapy
|
US20030108524A1
(en)
*
|
2001-10-18 |
2003-06-12 |
Melissa Diagana |
Vectors for expressing multiple transgenes
|
DE60237777D1
(de)
|
2001-10-19 |
2010-11-04 |
Vascular Biogenics Ltd |
Etzungen und verfahren zur gezielten herunterregulierung von angiogenese und zur krebstherapie
|
US20030086903A1
(en)
*
|
2001-11-02 |
2003-05-08 |
Genvec, Inc. |
Therapeutic regimen for treating cancer
|
AU2002343739A1
(en)
*
|
2001-11-14 |
2003-05-26 |
Medlogic Global Limited |
Improved therapy for topical diseases
|
JP4550421B2
(ja)
*
|
2001-12-12 |
2010-09-22 |
メイン・ファ−マ・インタ−ナショナル・プロプライエタリ−・リミテッド |
ウイルスの保存のための組成物
|
JP4413617B2
(ja)
|
2001-12-12 |
2010-02-10 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
Chlamydiatrachomatisに対する免疫化
|
US7662924B2
(en)
*
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
US20040025194A1
(en)
*
|
2002-02-22 |
2004-02-05 |
Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
US20040053836A1
(en)
*
|
2002-04-22 |
2004-03-18 |
Philipp Mayer-Kuckuk |
Method for modulating the production of a selected protein in vivo
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
US7977049B2
(en)
|
2002-08-09 |
2011-07-12 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
CA2503905A1
(en)
*
|
2002-09-16 |
2004-03-25 |
Plexxikon, Inc. |
Crystal structure of pim-1 kinase
|
US20040052161A1
(en)
*
|
2002-09-17 |
2004-03-18 |
Steven Liao |
Mechanical clock having wireless manipulation and adjustment function
|
CN101972478B
(zh)
*
|
2002-10-08 |
2012-10-31 |
免疫医疗公司 |
抗体治疗
|
US20050113324A1
(en)
*
|
2003-01-15 |
2005-05-26 |
Bondarev Igor E. |
Modulation of line-1 reverse transcriptase
|
US20050048573A1
(en)
*
|
2003-02-03 |
2005-03-03 |
Plexxikon, Inc. |
PDE5A crystal structure and uses
|
JP2007524374A
(ja)
*
|
2003-02-28 |
2007-08-30 |
プレキシコン,インコーポレーテッド |
Pyk2結晶構造および使用
|
WO2004085608A2
(en)
*
|
2003-03-27 |
2004-10-07 |
Newlink Genetics Corporation |
Methods for high throughput elucidation of transcriptional profiles and genome annotation
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
US20050079548A1
(en)
*
|
2003-07-07 |
2005-04-14 |
Plexxikon, Inc. |
Ligand development using PDE4B crystal structures
|
US20050164300A1
(en)
*
|
2003-09-15 |
2005-07-28 |
Plexxikon, Inc. |
Molecular scaffolds for kinase ligand development
|
EP1687032B1
(de)
*
|
2003-11-14 |
2010-02-24 |
Genvec, Inc. |
Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
|
CN1893981B
(zh)
*
|
2003-12-10 |
2011-03-23 |
坎基股份有限公司 |
用于治疗干扰素耐药性肿瘤的方法和组合物
|
US7504509B2
(en)
*
|
2003-12-19 |
2009-03-17 |
Plexxikon, Inc. |
Compounds and methods for development of Ret modulators
|
US20070066641A1
(en)
*
|
2003-12-19 |
2007-03-22 |
Prabha Ibrahim |
Compounds and methods for development of RET modulators
|
GB0406215D0
(en)
|
2004-03-19 |
2004-04-21 |
Procure Therapeutics Ltd |
Prostate stem cell
|
US8268324B2
(en)
|
2004-03-29 |
2012-09-18 |
Galpharma Co., Ltd. |
Modified galectin 9 proteins and use thereof
|
CN101031293A
(zh)
|
2004-05-06 |
2007-09-05 |
普莱希科公司 |
Pde4b抑制剂及其应用
|
ITMI20041032A1
(it)
*
|
2004-05-24 |
2004-08-24 |
Neuroscienze S C A R L |
Compositi farmaceutici
|
KR101169109B1
(ko)
|
2004-05-26 |
2012-07-26 |
싸이오서스 테라퓨틱스 엘티디. |
암 치료에 사용하기 위한 키메릭 아데노바이러스
|
US7498342B2
(en)
|
2004-06-17 |
2009-03-03 |
Plexxikon, Inc. |
Compounds modulating c-kit activity
|
GB0413702D0
(en)
*
|
2004-06-18 |
2004-07-21 |
Molmed Spa |
Thymidine kinase
|
EP2298896A1
(de)
|
2004-06-22 |
2011-03-23 |
The Board of Trustees of the University of Illinois |
Verfahren zur Inhibierung von Tumorzellwachstum mit FOXM1 siRNS
|
GB0416487D0
(en)
*
|
2004-07-23 |
2004-08-25 |
Isis Innovation |
Modified virus
|
EP1786474B1
(de)
*
|
2004-08-12 |
2011-06-01 |
Cedars-Sinai Medical Center |
Kombinierte gentherapie zur behandlung makroskopischer glioma
|
US20070212298A1
(en)
*
|
2004-08-25 |
2007-09-13 |
Prefix Suffix |
Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
|
CN101048407A
(zh)
*
|
2004-09-03 |
2007-10-03 |
普莱希科公司 |
双环杂芳基pde4b抑制剂
|
DE102004054215A1
(de)
*
|
2004-11-10 |
2006-05-11 |
Merck Patent Gmbh |
Pyridopyrimidinonderivate
|
KR100747646B1
(ko)
|
2005-02-25 |
2007-08-08 |
연세대학교 산학협력단 |
데코린 유전자를 포함하는 유전자 전달 시스템 및 이를 포함하는 약제학적 항종양 조성물
|
CN104997783A
(zh)
*
|
2005-03-25 |
2015-10-28 |
Alt解决方案公司 |
端粒酶阳性细胞中端粒长度的调节和癌症治疗
|
EP1885723A2
(de)
*
|
2005-05-17 |
2008-02-13 |
Plexxikon, Inc. |
Pyrrolo[2,3-b]pyridin-derivative als proteinkinase-hemmer
|
CA2609303A1
(en)
|
2005-05-18 |
2006-11-23 |
Alt Solutions, Inc. |
Pharmacological modulation of telomere length in cancer cells for prevention and treatment of cancer
|
WO2007002433A1
(en)
*
|
2005-06-22 |
2007-01-04 |
Plexxikon, Inc. |
Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
|
US7358489B2
(en)
*
|
2005-08-04 |
2008-04-15 |
Airware, Inc. |
Ultra low cost NDIR gas sensors
|
US20100015168A1
(en)
|
2006-06-09 |
2010-01-21 |
Novartis Ag |
Immunogenic compositions for streptococcus agalactiae
|
WO2008063888A2
(en)
|
2006-11-22 |
2008-05-29 |
Plexxikon, Inc. |
Compounds modulating c-fms and/or c-kit activity and uses therefor
|
EP2094701A2
(de)
|
2006-12-21 |
2009-09-02 |
Plexxikon, Inc. |
Verbindungen und verfahren zur kinase-modulation und anzeigen dafür
|
WO2008079909A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Plexxikon, Inc. |
Pyrrolo [2,3-b] pyridines as kinase modulators
|
PE20121126A1
(es)
*
|
2006-12-21 |
2012-08-24 |
Plexxikon Inc |
Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
|
WO2008083407A1
(en)
|
2007-01-02 |
2008-07-10 |
Aquabeam Llc |
Minimally invasive methods and devices for the treatment of prostate diseases
|
US9232959B2
(en)
|
2007-01-02 |
2016-01-12 |
Aquabeam, Llc |
Multi fluid tissue resection methods and devices
|
US8883493B2
(en)
*
|
2007-01-30 |
2014-11-11 |
Cedars-Sinai Medical Center |
Adenoviral vector comprising herpes simplex virus type 1 thymidine kinase and a transgene for increasing the expression of the transgene
|
WO2009012170A1
(en)
*
|
2007-07-13 |
2009-01-22 |
California Institute Of Technology |
Targeting the absence: homozygous dna deletions as signposts for cancer therapy
|
CN101808994B
(zh)
|
2007-07-17 |
2013-05-15 |
普莱希科公司 |
用于激酶调节的化合物和方法以及其适应症
|
WO2009018250A2
(en)
*
|
2007-07-30 |
2009-02-05 |
University Of Iowa Research Foundation |
Use of rpa4 and rpa4/rpa32 hybrid polypeptides for modulating cell proliferation
|
DE102007056488A1
(de)
*
|
2007-11-22 |
2009-07-23 |
Biontex Laboratories Gmbh |
Steigerung von Transfektionseffizienzen nicht-viraler Genliefersysteme durch Blockierung des angeborenen Immunsystems
|
US20100285056A1
(en)
|
2008-01-09 |
2010-11-11 |
Konkuk University Industrial Cooperation Corp. |
Baculovirus-Based Vaccines
|
EP2259742B1
(de)
|
2008-03-06 |
2020-01-01 |
AquaBeam LLC |
Gewebeablation und kauterisation mit in einem flüssigkeitsstrom getragener optischer energie
|
WO2010080985A1
(en)
|
2009-01-08 |
2010-07-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
ES2726702T3
(es)
|
2009-01-15 |
2019-10-08 |
Adaptive Biotechnologies Corp |
Perfilado de la inmunidad adaptativa y métodos para la generación de anticuerpos monoclonales
|
WO2010101921A2
(en)
|
2009-03-02 |
2010-09-10 |
The Regents Of The University Of California |
Tumor-selective e1a and e1b mutants
|
US9848904B2
(en)
|
2009-03-06 |
2017-12-26 |
Procept Biorobotics Corporation |
Tissue resection and treatment with shedding pulses
|
KR101764437B1
(ko)
|
2009-03-20 |
2017-08-02 |
메소블라스트, 아이엔씨. |
재프로그램된 다분화능 세포의 생성 방법
|
US9447089B2
(en)
|
2009-04-03 |
2016-09-20 |
Plexxikon Inc. |
Compositions and uses thereof
|
EP2248903A1
(de)
|
2009-04-29 |
2010-11-10 |
Universitat Autònoma De Barcelona |
Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
|
US8329724B2
(en)
|
2009-08-03 |
2012-12-11 |
Hoffmann-La Roche Inc. |
Process for the manufacture of pharmaceutically active compounds
|
US9605844B2
(en)
*
|
2009-09-01 |
2017-03-28 |
Cree, Inc. |
Lighting device with heat dissipation elements
|
GB0916997D0
(en)
|
2009-09-28 |
2009-11-11 |
Ark Therapeutics Ltd |
Combination therapy
|
UA105813C2
(uk)
|
2009-11-06 |
2014-06-25 |
Плексікон, Інк. |
Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
|
US20130040853A1
(en)
|
2010-01-21 |
2013-02-14 |
Dana-Farber Cancer Institute Inc. |
Context Specific Genetic Screen Platform to Aid in Gene Discovery and Target Validation
|
US9597379B1
(en)
|
2010-02-09 |
2017-03-21 |
David Gordon Bermudes |
Protease inhibitor combination with therapeutic proteins including antibodies
|
EP2571987B1
(de)
|
2010-05-21 |
2017-03-01 |
Peptimed, Inc. |
Reagenzien zur behandlung von krebs
|
US9539427B2
(en)
|
2010-11-08 |
2017-01-10 |
The Johns Hopkins University |
Methods for improving heart function
|
WO2012095548A2
(es)
|
2011-01-13 |
2012-07-19 |
Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) |
Compuestos para el tratamiento de enfermedades neurodegenerativas
|
AU2012214762B2
(en)
|
2011-02-07 |
2015-08-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
TWI558702B
(zh)
|
2011-02-21 |
2016-11-21 |
普雷辛肯公司 |
醫藥活性物質的固態形式
|
BR112013029163A2
(pt)
|
2011-05-17 |
2017-01-31 |
Plexxikon Inc |
modulação quinase e indicações dos mesmos
|
KR101293620B1
(ko)
|
2011-08-19 |
2013-08-13 |
국립암센터 |
트랜스-스플라이싱 라이보자임 및 암치료 유전자를 포함하는 재조합 아데노바이러스 및 이의 용도
|
US10093705B2
(en)
|
2011-09-13 |
2018-10-09 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using FNDC5
|
WO2013055911A1
(en)
|
2011-10-14 |
2013-04-18 |
Dana-Farber Cancer Institute, Inc. |
Znf365/zfp365 biomarker predictive of anti-cancer response
|
US9404090B2
(en)
|
2011-11-24 |
2016-08-02 |
Viromed Co., Ltd. |
Adenovirus producing novel cell line and the use thereof
|
CN108606773B
(zh)
|
2012-02-29 |
2020-08-11 |
普罗赛普特生物机器人公司 |
自动化图像引导的组织切除和处理
|
US9150570B2
(en)
|
2012-05-31 |
2015-10-06 |
Plexxikon Inc. |
Synthesis of heterocyclic compounds
|
US9259343B2
(en)
|
2012-07-06 |
2016-02-16 |
Newman Technologies LLC |
Device for mitigating plantar fasciitis
|
JP6403695B2
(ja)
|
2013-02-14 |
2018-10-10 |
プロセプト バイオロボティクス コーポレイション |
アクアアブレーションアクアビーム眼科手術方法および装置
|
JP6461971B2
(ja)
|
2013-09-06 |
2019-01-30 |
プロセプト バイオロボティクス コーポレイション |
飛散パルスを用いた組織切除および処置
|
SG11201602887QA
(en)
|
2013-10-25 |
2016-05-30 |
Psioxus Therapeutics Ltd |
Oncolytic adenoviruses armed with heterologous genes
|
JP6317440B2
(ja)
|
2013-10-29 |
2018-04-25 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
酸化ストレスを阻害するための方法および組成物
|
WO2015164743A2
(en)
|
2014-04-24 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
|
BR112016031037B1
(pt)
|
2014-06-30 |
2023-02-07 |
Procept Biorobotics Corporation |
Aparelho para ablação de tecido vascular
|
CN107072591B
(zh)
|
2014-09-05 |
2021-10-26 |
普罗赛普特生物机器人公司 |
与靶器官图像的治疗映射结合的医师控制的组织切除
|
WO2016057367A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
|
EP3204119B1
(de)
|
2014-10-09 |
2021-06-09 |
Dana-Farber Cancer Institute, Inc. |
Mehrfach-variabler il-2-dosierungsplan zur behandlung von immunerkrankungen
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
CN104740681A
(zh)
*
|
2015-03-02 |
2015-07-01 |
吉林大学 |
一种聚乳酸-羟基乙酸/腺病毒复合纳米纤维支架材料、制备方法及其应用
|
EP3265825A4
(de)
|
2015-03-06 |
2018-08-08 |
Dana-Farber Cancer Institute, Inc. |
Pd-l2-biomarker zur vorhersage von pd-1-weg-inhibitor-reaktionen bei ösophagogastrischem krebs
|
US10160755B2
(en)
|
2015-04-08 |
2018-12-25 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
AU2016256582B2
(en)
|
2015-04-30 |
2020-10-29 |
Akamis Bio Limited |
Oncolytic adenovirus encoding a B7 protein
|
WO2017019804A2
(en)
|
2015-07-28 |
2017-02-02 |
Plexxikon Inc. |
Compounds and methods for kinase modulation, and indications therefor
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
WO2017075329A2
(en)
|
2015-10-29 |
2017-05-04 |
Dana-Farber Cancer Institute, Inc. |
Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
|
BR112018011475A2
(pt)
|
2015-12-07 |
2018-12-04 |
Plexxikon Inc |
compostos e métodos para modulação de quinase e indicação para a mesma
|
EA201891021A1
(ru)
|
2015-12-17 |
2018-11-30 |
Псайоксус Терапьютикс Лимитед |
Аденовирус группы b, кодирующий антитело к комплексу tcr или фрагмент указанного антитела
|
AU2017238054B2
(en)
|
2016-03-21 |
2023-10-19 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
EP4273252A3
(de)
|
2016-08-29 |
2024-04-17 |
Akamis Bio Limited |
Adenovirus mit bispezifischem t-zell-engager (bite)
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
US11136409B2
(en)
|
2016-09-20 |
2021-10-05 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
|
TW201815766A
(zh)
|
2016-09-22 |
2018-05-01 |
美商普雷辛肯公司 |
用於ido及tdo調節之化合物及方法以及其適應症
|
US11180535B1
(en)
|
2016-12-07 |
2021-11-23 |
David Gordon Bermudes |
Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
|
AU2017395023B2
(en)
|
2016-12-23 |
2022-04-07 |
Plexxikon Inc. |
Compounds and methods for CDK8 modulation and indications therefor
|
WO2018226685A2
(en)
|
2017-06-06 |
2018-12-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
|
WO2018226846A1
(en)
|
2017-06-07 |
2018-12-13 |
Plexxikon Inc. |
Compounds and methods for kinase modulation
|
WO2019108777A1
(en)
|
2017-11-29 |
2019-06-06 |
Research Development Foundation |
Elimination of proliferating cells from stem cell-derived grafts
|
WO2019117632A1
(ko)
|
2017-12-13 |
2019-06-20 |
한양대학교 산학협력단 |
재조합 아데노바이러스 및 이를 포함하는 줄기세포
|
EP3810189A1
(de)
|
2018-06-19 |
2021-04-28 |
Armo Biosciences, Inc. |
Zusammensetzungen und verfahren zur verwendung von il-10-wirkstoffen in verbindung mit einer chimären antigen-rezeptor-zelltherapie
|
EP3876977A1
(de)
|
2018-11-06 |
2021-09-15 |
The Regents Of The University Of California |
Chimäre antigen-rezeptoren für phagocytose
|
WO2020094764A1
(en)
|
2018-11-07 |
2020-05-14 |
Consejo Superior De Investigaciones Científicas (Csic) |
Double and inducible suicide gene construct and its use in gene therapy
|
EP3962529A4
(de)
|
2019-04-30 |
2023-11-01 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-cx3cr1 und immuncheckpoint-blockierungsreagenzien
|
US11026973B2
(en)
|
2019-04-30 |
2021-06-08 |
Myeloid Therapeutics, Inc. |
Engineered phagocytic receptor compositions and methods of use thereof
|
MX2022002613A
(es)
|
2019-09-03 |
2022-06-02 |
Myeloid Therapeutics Inc |
Metodos y composiciones para la integracion del genoma.
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
WO2021146487A2
(en)
|
2020-01-14 |
2021-07-22 |
Synthekine, Inc. |
Il2 orthologs and methods of use
|
AU2021320327A1
(en)
|
2020-08-05 |
2023-03-23 |
Synthekine, Inc. |
IL10Rb binding molecules and methods of use
|
AU2021320226A1
(en)
|
2020-08-05 |
2023-03-23 |
Synthekine, Inc. |
gp130 binding molecules and methods of use
|
US20230272090A1
(en)
|
2020-08-05 |
2023-08-31 |
Sandro Vivona |
Il2rb binding molecules and methods of use
|
EP4192863A2
(de)
|
2020-08-05 |
2023-06-14 |
Synthekine, Inc. |
Il2rg-bindende moleküle und verfahren zur verwendung
|
KR20230061394A
(ko)
|
2020-08-05 |
2023-05-08 |
신테카인, 인크. |
IL10Ra 결합 분자 및 사용 방법
|
EP4208718A1
(de)
|
2020-09-02 |
2023-07-12 |
Johansson Swartling, Fredrik |
Vorhersage eines krebsrezidivs und behandlung von krebserkrankungen
|
EP4343004A3
(de)
|
2020-10-19 |
2024-09-11 |
Dana-Farber Cancer Institute, Inc. |
Keimbahnbiomarker einer klinischen reaktion und nutzen für eine immuncheckpoint-inhibitortherapie
|
AU2021376354A1
(en)
|
2020-11-04 |
2023-06-22 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
US20240024474A1
(en)
|
2020-11-13 |
2024-01-25 |
David Avigan |
Personalized fusion cell vaccines
|
WO2022197949A2
(en)
|
2021-03-17 |
2022-09-22 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
WO2023158732A1
(en)
|
2022-02-16 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
|